Compare prices and buy Orforglipron from 5 research peptide vendors - also called suppliers or sources. Updated daily.
Orforglipron (LY3502970, OWL-833) is a small-molecule, non-peptide GLP-1 receptor partial agonist discovered by Chugai Pharmaceutical and developed by Eli Lilly as an oral tablet. Unlike oral semaglutide, it needs no absorption enhancer. FDA-approved as Foundayo for chronic weight management in adults with obesity, or with overweight and a weight-related condition.
For research purposes only. Not medical advice.
Orforglipron (Eli Lilly's LY3502970, originally OWL833) is not a peptide. It is a synthetic small molecule with the formula C48H48F2N10O5, discovered by Chugai Pharmaceutical and licensed to Lilly in 2018. PeptideScouter catalogues it beside semaglutide and tirzepatide because it acts on the same receptor and is sold by the same vendors, not because it shares their chemistry.
Orforglipron activates the GLP-1 receptor without resembling GLP-1. In the high-resolution structure Lilly scientists published in PNAS in 2020, it sits in a distinct pocket in the upper part of the receptor's helical bundle, held by the extracellular domain and several transmembrane helices. The same paper describes it as a partial agonist biased toward G-protein signaling over beta-arrestin recruitment.
That binding depends on a tryptophan residue specific to primate GLP-1 receptors. The FDA label states that orforglipron is not pharmacologically active in rats or mice, so preclinical efficacy work used mice engineered to carry the human receptor, plus nonhuman primates. The label's boxed thyroid C-cell tumor warning therefore rests on the GLP-1 class: orforglipron produced no tumors in rodents, where it is inactive, and the label states that the human relevance of the class finding has not been determined.
Peptides are digested in the gut. Oral semaglutide gets around this with the absorption enhancer SNAC, and its label requires an empty stomach with limited water and reports an absolute oral bioavailability of roughly 0.4% to 1%. A small molecule needs no such workaround, and the Foundayo label allows it to be taken with or without food. The label gives a half-life of about 29 to 49 hours.
In ACHIEVE-3, HbA1c fell 1.71 and 1.91 points with the two orforglipron doses versus 1.23 and 1.47 with oral semaglutide. The authors also reported more gastrointestinal events, more discontinuations for adverse events and a larger pulse-rate increase with orforglipron. Lilly's own ATTAIN-1 figure, for participants who stayed on treatment, was 12.4% versus 0.9%.
The FDA approved orforglipron as Foundayo on April 1, 2026 (NDA 220934), an oral tablet for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition. As of October 2026 the US label covers weight management only. Lilly said in June 2026 that it planned to submit orforglipron to the FDA for type 2 diabetes on the strength of the ACHIEVE trials.
Because orforglipron is the active ingredient of an approved drug, its status is set by that approval rather than by the FDA bulk-substance nomination lists that govern older research peptides. Research-grade capsules sold by vendors are not Foundayo.
Foundayo contains orforglipron calcium, and the label states each tablet strength as the equivalent mass of the free base, the form identified by this page's CAS number (2212020-52-3). The calcium salt is about 2% heavier per molecule. A vendor label that does not name the form leaves that basis unstated. Some vendors sell orforglipron under the code FG-O.
PeptideScouter computes a cost per milligram only for vials, so capsule listings appear on this page but not in the site's per-milligram comparisons.
No. Orforglipron is a synthetic small molecule (formula C48H48F2N10O5) that activates the GLP-1 receptor, the same target as the peptide drugs semaglutide and tirzepatide, without resembling GLP-1 structurally. It was discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. PeptideScouter lists it alongside GLP-1 peptides because it shares their receptor target and is sold by the same research vendors.
Yes. The FDA approved orforglipron as Foundayo on April 1, 2026, as a prescription tablet for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition. As of October 2026 the US label does not cover type 2 diabetes, an indication Lilly said in June 2026 it planned to submit. Research-grade orforglipron sold by peptide vendors is not Foundayo and is offered for laboratory research only, not for human consumption.
Oral semaglutide is a peptide that relies on the absorption enhancer SNAC, and its label requires taking it on an empty stomach with limited water. Orforglipron is a small molecule absorbed without an enhancer, and its label allows it to be taken with or without food. In ACHIEVE-3, the first head-to-head Phase 3 trial of the two in type 2 diabetes (The Lancet, 2026), orforglipron produced larger HbA1c reductions over 52 weeks, along with more gastrointestinal events and more discontinuations for adverse events.
PeptideScouter computes cost per milligram only for vial listings. Research vendors sell orforglipron as capsules, so its listings appear on this page with their package prices but are left out of the site's per-milligram comparisons. A capsule label may also leave unstated whether its mass refers to the free base or a salt form such as orforglipron calcium, the form in the approved tablet.
Its binding to the GLP-1 receptor depends on a tryptophan residue specific to primate receptors. The FDA label states that orforglipron is not pharmacologically active in rats or mice, so Lilly's preclinical efficacy studies used mice engineered to carry the human GLP-1 receptor, along with nonhuman primates.
Orforglipron is sold by 5 research peptide vendors indexed on PeptideScouter, with 5 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 5 indexed research peptide vendors currently have Orforglipron in stock. Stock state is refreshed daily from each vendor's catalog.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 5 vendors listing Orforglipron publish a PeptideScouter code, worth 10% to 15% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
5 research peptide vendors currently list Orforglipron on PeptideScouter. We track 5 listings across size and kit variants.
Orforglipron's CAS Registry Number is 2212020-52-3. It is also sold as FG-O, GLP-1 (Orforglipron).
